Study details
Enrolling now
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
Tiffany J. Braley, MD, MS
NCT IDNCT05269628ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
166
Study length
about 5.4 years
Ages
18–65
Locations
1 site in MI
What this study is about
This trial is testing whether cannabidiol (CBD), tetrahydrocannabinol (THC), or both, can improve sleep and reduce pain in people with multiple sclerosis (MS). The goal is to understand how CBD and/or THC may help with these conditions.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cannabidiol (CBD)
- 2.Take Placebo CBD
- 3.Take Placebo THC
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
cannabinoid, cannabidiol, dronabinol
Drug routes
oral (Oral Solution)
Body systems
Neurology